:: Volume 14, Issue 2 (12-2020) ::
Iran J Virol 2020, 14(2): 23-28 Back to browse issues page
Human Reovirus Serotype 3 Effectively Targets Huh-7 Cells
Reihaneh Kazemi, Angila Ataei-Pirkooh, Mohammad Reza Aghasadeghi, Mohammad Hossein Modaresi, Mojtaba Hamidi-Fard *
Hepatitis & AIDS department, Pasteur institute of Iran, Tehran, Iran.
Abstract:   (1551 Views)
Background and Aims: Huh-7 is a cell line that was derived from a liver tumor of a Japanese man. Hepatocellular carcinoma (HCC) is considered as a primary liver cancer. Highly resistant tumor to treatment which causes the death of many patients annually. Thus, targeting the cancer cells by using a new method could be effective in therapy of this cancer. Reoviruses are oncolytic viruses that can infect and kill tumor cells, which have an activated Ras signaling pathways, while normal cells are resistant to infection and replication of these viruses. The aim of this study was to evaluate the effect of oncolytic human reovirus on Huh 7 cell line in vitro. Materials and Methods: Human reovirus serotype 3, Huh-7 cell line, and normal human fibroblasts were used in this study. After virus purification and plaque assay, human reoviruses were inoculated into the Huh-7 cells and human normal fibroblasts as negative control. Virus cytopathic effect, cell viability, and viral RNA replication were assessed at the different time of post-infection. Results: Virus cytopathic effects and cell lysis were clearly observed and reovirus RNA replication was detected in the Huh-7 cells, whereas normal human fibroblasts were resistant against reovirus infection. Conclusion: The result of the present study showed that human reoviruses serotype 3 can destroy the Huh-7 cells. Accordingly, the use of human reovirus could be considered as a potential therapy for HCC and liver cancer.
Keywords: hepatocellular carcinoma (HCC), Huh-7, oncolytic virus, reovirus
Full-Text [PDF 659 kb]   (486 Downloads)    
Type of Study: Original article | Subject: General
Received: 2020/09/10 | Accepted: 2020/12/20 | Published: 2020/12/20

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 2 (12-2020) Back to browse issues page